Rose Surgicals And Pharma Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 24-10-2024
- Paid Up Capital ₹ 4.00 M
as on 24-10-2024
- Company Age 13 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.75 Cr
as on 24-10-2024
- Satisfied Charges ₹ 9.18 Cr
as on 24-10-2024
- Revenue -22.21%
(FY 2023)
- Profit -8.97%
(FY 2023)
- Ebitda 11.92%
(FY 2023)
- Net Worth 20.22%
(FY 2023)
- Total Assets 32.09%
(FY 2023)
About Rose Surgicals And Pharma
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 4.00 M.
The company currently has active open charges totaling ₹5.75 Cr. The company has closed loans amounting to ₹9.18 Cr, as per Ministry of Corporate Affairs (MCA) records.
Neetu Singh and Vivek Gangwar serve as directors at the Company.
- CIN/LLPIN
U51909DL2011PTC217607
- Company No.
217607
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Apr 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rose Surgicals And Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neetu Singh  | Director | 18-Jul-2022 | Current |
| Vivek Gangwar | Director | 27-Dec-2014 | Current |
Financial Performance of Rose Surgicals And Pharma.
Rose Surgicals And Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 22.21% decrease. The company also saw a slight decrease in profitability, with a 8.97% decrease in profit. The company's net worth Soared by an impressive increase of 20.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rose Surgicals And Pharma?
In 2023, Rose Surgicals And Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Roseley Foods Private LimitedActive 5 years 11 monthsNeetu Singh and Vivek Gangwar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 19 Dec 2022 | ₹5.75 Cr | Open |
Others Creation Date: 30 Jan 2023 | ₹2.00 Cr | Satisfied |
Others Creation Date: 17 Jun 2020 | ₹7.00 M | Satisfied |
How Many Employees Work at Rose Surgicals And Pharma?
Unlock and access historical data on people associated with Rose Surgicals And Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rose Surgicals And Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rose Surgicals And Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
